Scientists hunt safe doses for brain tumor drug cocktail
NCT ID NCT06095375
Summary
This early-stage study aimed to find safe doses of a drug called regorafenib when added to standard treatment for a fast-growing brain tumor called glioblastoma. Researchers tested the drug combination in 21 adults who had recently been diagnosed. The main goal was to determine how much regorafenib could be given without causing severe side effects, both during initial radiation/chemotherapy and during follow-up maintenance therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, IDH-WILDTYPE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Humanitas Research Hospital
Rozzano, 20089, Italy
-
Istituto Oncologico Veneto IRCCS
Padua, 35128, Italy
Conditions
Explore the condition pages connected to this study.